

May 17, 2021



## Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit

REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- **Rezolute, Inc.** (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases caused by chronic glucose imbalance, today announced that management will present at the Oppenheimer Rare and Orphan Disease Summit. The presentation will be available on-demand starting at 8:00 AM ET on Friday, May 21, 2021.

A webcast of the presentation will be available for 90 days on the "IR Calendar" page within the Investors section of the Rezolute website at <https://ir.rezolutebio.com/ir-calendar>.

### **About Rezolute, Inc.**

Rezolute is advancing novel therapies for diseases caused by chronic glucose imbalance. The Company's lead clinical asset, RZ358, is in Phase 2b development for treatment of congenital hyperinsulinism (CHI), a rare pediatric endocrine disorder. The Company is also developing RZ402, an orally available plasma kallikrein inhibitor, for the treatment of diabetic macular edema. For more information, visit [www.rezolutebio.com](http://www.rezolutebio.com) or follow us on Twitter.

### **Forward-Looking Statements**

This release, like many written and oral communications presented by Rezolute, Inc. and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.

### **Media Contact**

[rezolute@argotpartners.com](mailto:rezolute@argotpartners.com)

## Investor Contact

[rezolute@argotpartners.com](mailto:rezolute@argotpartners.com)

REZOLUTE 

Source: Rezolute, Inc.